RO117110B1 - POLIPEPTIDA LIGAND mpl, ACID NUCLEIC, CARE O CODIFICA, VECTOR DE EXPRESIE, PROCEDEU PENTRU PRODUCEREA POLIPEPTIDEI LIGAND, SI COMPOZITIE FARMACEUTICA CU ACEASTA - Google Patents

Info

Publication number

RO117110B1

RO117110B1 RO96-01347A RO9601347A RO117110B1 RO 117110 B1 RO117110 B1 RO 117110B1 RO 9601347 A RO9601347 A RO 9601347A RO 117110 B1 RO117110 B1 RO 117110B1

Authority

RO

Romania

Prior art keywords

sequence

mpl ligand

polypeptide

seq

mpl

Prior art date

1994-01-03

Links

• Espacenet
• Global Dossier
• Discuss

• 108010041111 Thrombopoietin Proteins 0.000 title claims abstract description 479
• 102000036693 Thrombopoietin Human genes 0.000 title claims abstract description 475
• 238000000034 method Methods 0.000 title claims abstract description 134
• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 130
• 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 121
• 229920001184 polypeptide Polymers 0.000 title claims abstract description 119
• 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 73
• 102000039446 nucleic acids Human genes 0.000 title claims abstract description 63
• 108020004707 nucleic acids Proteins 0.000 title claims abstract description 63
• 230000008569 process Effects 0.000 title claims abstract description 27
• 239000013604 expression vector Substances 0.000 title claims abstract description 25
• 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
• 239000003446 ligand Substances 0.000 title claims description 123
• 239000012634 fragment Substances 0.000 claims abstract description 102
• 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 74
• 125000000539 amino acid group Chemical group 0.000 claims abstract description 37
• 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims abstract description 13
• 230000000295 complement effect Effects 0.000 claims abstract description 13
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 11
• 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 claims abstract description 7
• 102000053400 human TPO Human genes 0.000 claims abstract description 7
• 125000003277 amino group Chemical group 0.000 claims abstract description 5
• 210000004027 cell Anatomy 0.000 claims description 271
• 108020004414 DNA Proteins 0.000 claims description 165
• 241000282414 Homo sapiens Species 0.000 claims description 134
• 108090000623 proteins and genes Proteins 0.000 claims description 132
• 102000004169 proteins and genes Human genes 0.000 claims description 92
• 230000027455 binding Effects 0.000 claims description 48
• 239000002773 nucleotide Substances 0.000 claims description 44
• 125000003729 nucleotide group Chemical group 0.000 claims description 44
• 239000013612 plasmid Substances 0.000 claims description 42
• 150000001413 amino acids Chemical group 0.000 claims description 39
• 108060003951 Immunoglobulin Proteins 0.000 claims description 34
• 102000018358 immunoglobulin Human genes 0.000 claims description 34
• 210000004369 blood Anatomy 0.000 claims description 32
• 239000008280 blood Substances 0.000 claims description 32
• 108010002386 Interleukin-3 Proteins 0.000 claims description 31
• 238000004113 cell culture Methods 0.000 claims description 26
• 102000004127 Cytokines Human genes 0.000 claims description 25
• 108090000695 Cytokines Proteins 0.000 claims description 25
• 238000000746 purification Methods 0.000 claims description 25
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
• 239000003795 chemical substances by application Substances 0.000 claims description 23
• 238000012360 testing method Methods 0.000 claims description 22
• 241000588724 Escherichia coli Species 0.000 claims description 19
• 230000001965 increasing effect Effects 0.000 claims description 19
• 238000013518 transcription Methods 0.000 claims description 19
• 230000035897 transcription Effects 0.000 claims description 19
• 238000010348 incorporation Methods 0.000 claims description 18
• 241000124008 Mammalia Species 0.000 claims description 15
• 210000004408 hybridoma Anatomy 0.000 claims description 14
• 108090001005 Interleukin-6 Proteins 0.000 claims description 11
• 102000015696 Interleukins Human genes 0.000 claims description 11
• 108010063738 Interleukins Proteins 0.000 claims description 11
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 10
• 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 9
• 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 9
• 102000000589 Interleukin-1 Human genes 0.000 claims description 9
• 108010002352 Interleukin-1 Proteins 0.000 claims description 9
• 230000001419 dependent effect Effects 0.000 claims description 9
• 238000005063 solubilization Methods 0.000 claims description 9
• 230000007928 solubilization Effects 0.000 claims description 9
• 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 8
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 8
• 239000003623 enhancer Substances 0.000 claims description 8
• 102000044890 human EPO Human genes 0.000 claims description 8
• 238000005406 washing Methods 0.000 claims description 8
• 239000008188 pellet Substances 0.000 claims description 7
• 229940047122 interleukins Drugs 0.000 claims description 6
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
• 108010002335 Interleukin-9 Proteins 0.000 claims description 5
• 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 5
• 230000010261 cell growth Effects 0.000 claims description 5
• 210000004698 lymphocyte Anatomy 0.000 claims description 5
• 108010002350 Interleukin-2 Proteins 0.000 claims description 4
• 102000000588 Interleukin-2 Human genes 0.000 claims description 4
• 108010002616 Interleukin-5 Proteins 0.000 claims description 4
• 108010002586 Interleukin-7 Proteins 0.000 claims description 4
• 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 4
• 238000005273 aeration Methods 0.000 claims description 4
• 229940047120 colony stimulating factors Drugs 0.000 claims description 4
• 230000003053 immunization Effects 0.000 claims description 4
• 108090001007 Interleukin-8 Proteins 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 150000002482 oligosaccharides Chemical class 0.000 claims description 3
• 101001006370 Actinobacillus suis Hemolysin Proteins 0.000 claims description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
• 101100184723 Homo sapiens PMPCA gene Proteins 0.000 claims description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
• 102100025321 Mitochondrial-processing peptidase subunit alpha Human genes 0.000 claims description 2
• 125000004112 carboxyamino group Chemical group [H]OC(=O)N([H])[*] 0.000 claims description 2
• 238000003306 harvesting Methods 0.000 claims description 2
• 230000002103 transcriptional effect Effects 0.000 claims description 2
• 230000001131 transforming effect Effects 0.000 claims description 2
• 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
• 239000006143 cell culture medium Substances 0.000 claims 1
• 229920001542 oligosaccharide Polymers 0.000 claims 1
• 210000004899 c-terminal region Anatomy 0.000 abstract description 11
• 210000001772 blood platelet Anatomy 0.000 description 96
• 235000018102 proteins Nutrition 0.000 description 91
• 230000000694 effects Effects 0.000 description 72
• 239000013598 vector Substances 0.000 description 60
• 210000003593 megakaryocyte Anatomy 0.000 description 52
• 206010043554 thrombocytopenia Diseases 0.000 description 45
• 235000001014 amino acid Nutrition 0.000 description 44
• 230000014509 gene expression Effects 0.000 description 44
• 108091034117 Oligonucleotide Proteins 0.000 description 43
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 43
• 239000002299 complementary DNA Substances 0.000 description 41
• 102000003951 Erythropoietin Human genes 0.000 description 40
• 108090000394 Erythropoietin Proteins 0.000 description 40
• 229940024606 amino acid Drugs 0.000 description 39
• 229940105423 erythropoietin Drugs 0.000 description 39
• 238000003752 polymerase chain reaction Methods 0.000 description 37
• 238000004519 manufacturing process Methods 0.000 description 34
• 102000005962 receptors Human genes 0.000 description 33
• 108020003175 receptors Proteins 0.000 description 33
• 102100039064 Interleukin-3 Human genes 0.000 description 32
• 238000012217 deletion Methods 0.000 description 31
• 230000037430 deletion Effects 0.000 description 31
• 210000002381 plasma Anatomy 0.000 description 31
• 241001529936 Murinae Species 0.000 description 29
• 229940076264 interleukin-3 Drugs 0.000 description 28
• 230000004071 biological effect Effects 0.000 description 27
• 230000035755 proliferation Effects 0.000 description 27
• 239000000523 sample Substances 0.000 description 26
• 241000699666 Mus <mouse, genus> Species 0.000 description 25
• 230000035772 mutation Effects 0.000 description 25
• 238000006467 substitution reaction Methods 0.000 description 25
• 241000699670 Mus sp. Species 0.000 description 24
• 229920002684 Sepharose Polymers 0.000 description 24
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 24
• 239000013615 primer Substances 0.000 description 24
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 23
• 235000018417 cysteine Nutrition 0.000 description 23
• 239000002243 precursor Substances 0.000 description 23
• 108010076504 Protein Sorting Signals Proteins 0.000 description 22
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 22
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 22
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 22
• 239000000872 buffer Substances 0.000 description 22
• 230000035800 maturation Effects 0.000 description 21
• 238000003556 assay Methods 0.000 description 20
• 238000006243 chemical reaction Methods 0.000 description 20
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 20
• 230000004069 differentiation Effects 0.000 description 20
• 230000004927 fusion Effects 0.000 description 20
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
• 239000000499 gel Substances 0.000 description 19
• 238000000338 in vitro Methods 0.000 description 19
• 238000001727 in vivo Methods 0.000 description 19
• 241001465754 Metazoa Species 0.000 description 18
• 238000004458 analytical method Methods 0.000 description 18
• 230000015572 biosynthetic process Effects 0.000 description 18
• -1 clostripaine Proteins 0.000 description 18
• 238000011282 treatment Methods 0.000 description 18
• 102000004190 Enzymes Human genes 0.000 description 17
• 108090000790 Enzymes Proteins 0.000 description 17
• 239000000427 antigen Substances 0.000 description 17
• 230000000890 antigenic effect Effects 0.000 description 17
• 108091007433 antigens Proteins 0.000 description 17
• 102000036639 antigens Human genes 0.000 description 17
• 229940088598 enzyme Drugs 0.000 description 17
• 239000003102 growth factor Substances 0.000 description 17
• 230000003394 haemopoietic effect Effects 0.000 description 17
• 238000003780 insertion Methods 0.000 description 17
• 230000037431 insertion Effects 0.000 description 17
• 210000002966 serum Anatomy 0.000 description 17
• 241000894007 species Species 0.000 description 17
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
• 230000013595 glycosylation Effects 0.000 description 16
• 238000006206 glycosylation reaction Methods 0.000 description 16
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 16
• 239000000047 product Substances 0.000 description 16
• 210000000130 stem cell Anatomy 0.000 description 16
• 230000004936 stimulating effect Effects 0.000 description 16
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
• 230000006378 damage Effects 0.000 description 15
• 230000006870 function Effects 0.000 description 15
• 230000012010 growth Effects 0.000 description 15
• 208000028622 Immune thrombocytopenia Diseases 0.000 description 14
• 238000003776 cleavage reaction Methods 0.000 description 14
• 230000004048 modification Effects 0.000 description 14
• 238000012986 modification Methods 0.000 description 14
• 238000002703 mutagenesis Methods 0.000 description 14
• 231100000350 mutagenesis Toxicity 0.000 description 14
• 230000007017 scission Effects 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
• 210000000601 blood cell Anatomy 0.000 description 13
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 13
• 102000003675 cytokine receptors Human genes 0.000 description 13
• 108010057085 cytokine receptors Proteins 0.000 description 13
• 230000029087 digestion Effects 0.000 description 13
• 239000000203 mixture Substances 0.000 description 13
• 108091008146 restriction endonucleases Proteins 0.000 description 13
• 239000001963 growth medium Substances 0.000 description 12
• 229940072221 immunoglobulins Drugs 0.000 description 12
• 238000000926 separation method Methods 0.000 description 12
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 230000001361 thrombopoietic effect Effects 0.000 description 12
• 108091026890 Coding region Proteins 0.000 description 11
• 241000282898 Sus scrofa Species 0.000 description 11
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
• 230000003321 amplification Effects 0.000 description 11
• 210000001185 bone marrow Anatomy 0.000 description 11
• 239000004202 carbamide Substances 0.000 description 11
• 229960003180 glutathione Drugs 0.000 description 11
• 210000004962 mammalian cell Anatomy 0.000 description 11
• 239000000463 material Substances 0.000 description 11
• 238000003199 nucleic acid amplification method Methods 0.000 description 11
• 230000010076 replication Effects 0.000 description 11
• 230000000638 stimulation Effects 0.000 description 11
• 230000009466 transformation Effects 0.000 description 11
• 241000894006 Bacteria Species 0.000 description 10
• 102000004889 Interleukin-6 Human genes 0.000 description 10
• 230000004988 N-glycosylation Effects 0.000 description 10
• 108010022394 Threonine synthase Proteins 0.000 description 10
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
• 239000003638 chemical reducing agent Substances 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 102000004419 dihydrofolate reductase Human genes 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 10
• 210000003734 kidney Anatomy 0.000 description 10
• 210000004185 liver Anatomy 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• 230000002062 proliferating effect Effects 0.000 description 10
• 230000002829 reductive effect Effects 0.000 description 10
• 229940104230 thymidine Drugs 0.000 description 10
• 108010053070 Glutathione Disulfide Proteins 0.000 description 9
• 102100020880 Kit ligand Human genes 0.000 description 9
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
• 108010029485 Protein Isoforms Proteins 0.000 description 9
• 102000001708 Protein Isoforms Human genes 0.000 description 9
• 230000001605 fetal effect Effects 0.000 description 9
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 210000004379 membrane Anatomy 0.000 description 9
• 238000011084 recovery Methods 0.000 description 9
• 239000006176 redox buffer Substances 0.000 description 9
• 239000011780 sodium chloride Substances 0.000 description 9
• 238000010561 standard procedure Methods 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 238000002965 ELISA Methods 0.000 description 8
• 241000196324 Embryophyta Species 0.000 description 8
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
• 108090000177 Interleukin-11 Proteins 0.000 description 8
• 102000003815 Interleukin-11 Human genes 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 150000001720 carbohydrates Chemical group 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 230000003196 chaotropic effect Effects 0.000 description 8
• 230000001086 cytosolic effect Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 239000003814 drug Substances 0.000 description 8
• 239000012636 effector Substances 0.000 description 8
• 238000009396 hybridization Methods 0.000 description 8
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
• 210000003292 kidney cell Anatomy 0.000 description 8
• 239000012071 phase Substances 0.000 description 8
• 230000017854 proteolysis Effects 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• 108020004705 Codon Proteins 0.000 description 7
• 102000003886 Glycoproteins Human genes 0.000 description 7
• 108090000288 Glycoproteins Proteins 0.000 description 7
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 7
• 108700026244 Open Reading Frames Proteins 0.000 description 7
• 241000283973 Oryctolagus cuniculus Species 0.000 description 7
• 108010039445 Stem Cell Factor Proteins 0.000 description 7
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 230000002255 enzymatic effect Effects 0.000 description 7
• 238000002474 experimental method Methods 0.000 description 7
• 238000004128 high performance liquid chromatography Methods 0.000 description 7
• 230000006698 induction Effects 0.000 description 7
• 239000000543 intermediate Substances 0.000 description 7
• 238000002955 isolation Methods 0.000 description 7
• 244000005700 microbiome Species 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 230000003612 virological effect Effects 0.000 description 7
• 208000030507 AIDS Diseases 0.000 description 6
• 102000053602 DNA Human genes 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• 108010024636 Glutathione Proteins 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 6
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 6
• 229930193140 Neomycin Natural products 0.000 description 6
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 238000010367 cloning Methods 0.000 description 6
• 230000001332 colony forming effect Effects 0.000 description 6
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
• 210000003743 erythrocyte Anatomy 0.000 description 6
• 239000003862 glucocorticoid Substances 0.000 description 6
• 210000003714 granulocyte Anatomy 0.000 description 6
• 230000001900 immune effect Effects 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 229960004927 neomycin Drugs 0.000 description 6
• 239000007800 oxidant agent Substances 0.000 description 6
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 239000011537 solubilization buffer Substances 0.000 description 6
• 239000006228 supernatant Substances 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 230000035921 thrombopoiesis Effects 0.000 description 6
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
• 108091035707 Consensus sequence Proteins 0.000 description 5
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 5
• 208000031886 HIV Infections Diseases 0.000 description 5
• 208000037357 HIV infectious disease Diseases 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
• 108090001090 Lectins Proteins 0.000 description 5
• 102000004856 Lectins Human genes 0.000 description 5
• 241000282320 Panthera leo Species 0.000 description 5
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
• 210000001744 T-lymphocyte Anatomy 0.000 description 5
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 229940088597 hormone Drugs 0.000 description 5
• 239000005556 hormone Substances 0.000 description 5
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
• 239000002523 lectin Substances 0.000 description 5
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 5
• 238000010911 splenectomy Methods 0.000 description 5
• 230000010474 transient expression Effects 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 241000282693 Cercopithecidae Species 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• 241000699802 Cricetulus griseus Species 0.000 description 4
• 108010017826 DNA Polymerase I Proteins 0.000 description 4
• 102000004594 DNA Polymerase I Human genes 0.000 description 4
• 230000004544 DNA amplification Effects 0.000 description 4
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 4
• 108091027305 Heteroduplex Proteins 0.000 description 4
• 102000004877 Insulin Human genes 0.000 description 4
• 108090001061 Insulin Proteins 0.000 description 4
• 102000004388 Interleukin-4 Human genes 0.000 description 4
• 108090000978 Interleukin-4 Proteins 0.000 description 4
• 102000000585 Interleukin-9 Human genes 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• 102000004058 Leukemia inhibitory factor Human genes 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 4
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 239000004365 Protease Substances 0.000 description 4
• 241000283984 Rodentia Species 0.000 description 4
• 241000282887 Suidae Species 0.000 description 4
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
• 229910052799 carbon Inorganic materials 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 230000004087 circulation Effects 0.000 description 4
• 210000000805 cytoplasm Anatomy 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 238000009795 derivation Methods 0.000 description 4
• 239000003599 detergent Substances 0.000 description 4
• 238000004520 electroporation Methods 0.000 description 4
• 210000003979 eosinophil Anatomy 0.000 description 4
• 210000003527 eukaryotic cell Anatomy 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
• 229960004198 guanidine Drugs 0.000 description 4
• 230000002209 hydrophobic effect Effects 0.000 description 4
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 229940125396 insulin Drugs 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 210000005229 liver cell Anatomy 0.000 description 4
• 238000010369 molecular cloning Methods 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• 239000002751 oligonucleotide probe Substances 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
• 210000001778 pluripotent stem cell Anatomy 0.000 description 4
• 229920002401 polyacrylamide Polymers 0.000 description 4
• 238000001556 precipitation Methods 0.000 description 4
• 230000006337 proteolytic cleavage Effects 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 239000001509 sodium citrate Substances 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 230000003582 thrombocytopenic effect Effects 0.000 description 4
• 238000000844 transformation Methods 0.000 description 4
• 238000000108 ultra-filtration Methods 0.000 description 4
• 238000011144 upstream manufacturing Methods 0.000 description 4
• 229920000936 Agarose Polymers 0.000 description 3
• 241000589155 Agrobacterium tumefaciens Species 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• 241000193830 Bacillus <bacterium> Species 0.000 description 3
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• 241000233866 Fungi Species 0.000 description 3
• 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 3
• 108010051696 Growth Hormone Proteins 0.000 description 3
• 102000018997 Growth Hormone Human genes 0.000 description 3
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
• FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000008607 Integrin beta3 Human genes 0.000 description 3
• 108010020950 Integrin beta3 Proteins 0.000 description 3
• 102000003996 Interferon-beta Human genes 0.000 description 3
• 108090000467 Interferon-beta Proteins 0.000 description 3
• 102100039897 Interleukin-5 Human genes 0.000 description 3
• 102100021592 Interleukin-7 Human genes 0.000 description 3
• 102000003960 Ligases Human genes 0.000 description 3
• 108090000364 Ligases Proteins 0.000 description 3
• 102000009151 Luteinizing Hormone Human genes 0.000 description 3
• 108010073521 Luteinizing Hormone Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• VXOKDLACQICQFA-UHFFFAOYSA-N N-Desethylamiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCNCC)C(I)=C1 VXOKDLACQICQFA-UHFFFAOYSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 108090000445 Parathyroid hormone Proteins 0.000 description 3
• 241000276498 Pollachius virens Species 0.000 description 3
• 108091036407 Polyadenylation Proteins 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
• 108020004682 Single-Stranded DNA Proteins 0.000 description 3
• 238000002105 Southern blotting Methods 0.000 description 3
• 206010041660 Splenomegaly Diseases 0.000 description 3
• 108091081024 Start codon Proteins 0.000 description 3
• 108091036066 Three prime untranslated region Proteins 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 208000005485 Thrombocytosis Diseases 0.000 description 3
• 102000006601 Thymidine Kinase Human genes 0.000 description 3
• 108020004440 Thymidine kinase Proteins 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000000702 anti-platelet effect Effects 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 239000003146 anticoagulant agent Substances 0.000 description 3
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 210000003651 basophil Anatomy 0.000 description 3
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
• 230000000740 bleeding effect Effects 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 238000001516 cell proliferation assay Methods 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 239000003636 conditioned culture medium Substances 0.000 description 3
• 238000011109 contamination Methods 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 239000003431 cross linking reagent Substances 0.000 description 3
• 238000012258 culturing Methods 0.000 description 3
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 239000005547 deoxyribonucleotide Substances 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 201000010099 disease Diseases 0.000 description 3
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
• 150000002019 disulfides Chemical class 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 239000012149 elution buffer Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 238000001976 enzyme digestion Methods 0.000 description 3
• 230000000925 erythroid effect Effects 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 230000002349 favourable effect Effects 0.000 description 3
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
• 239000000122 growth hormone Substances 0.000 description 3
• 210000000777 hematopoietic system Anatomy 0.000 description 3
• 201000004108 hypersplenism Diseases 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 238000011532 immunohistochemical staining Methods 0.000 description 3
• 238000012744 immunostaining Methods 0.000 description 3
• 230000008676 import Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 239000002198 insoluble material Substances 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 238000011068 loading method Methods 0.000 description 3
• 229940040129 luteinizing hormone Drugs 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 210000005194 mastoid cells Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 210000005074 megakaryoblast Anatomy 0.000 description 3
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
• 210000000066 myeloid cell Anatomy 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 108091027963 non-coding RNA Proteins 0.000 description 3
• 102000042567 non-coding RNA Human genes 0.000 description 3
• 235000015097 nutrients Nutrition 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
• 229920000053 polysorbate 80 Polymers 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 235000019419 proteases Nutrition 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 230000035939 shock Effects 0.000 description 3
• 229910052709 silver Inorganic materials 0.000 description 3
• 239000004332 silver Substances 0.000 description 3
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
• 239000001488 sodium phosphate Substances 0.000 description 3
• 229910000162 sodium phosphate Inorganic materials 0.000 description 3
• VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 3
• 239000002195 soluble material Substances 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 230000003393 splenic effect Effects 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 description 3
• 230000001732 thrombotic effect Effects 0.000 description 3
• 230000005030 transcription termination Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
• 108010087967 type I signal peptidase Proteins 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
• GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 2
• 102000013563 Acid Phosphatase Human genes 0.000 description 2
• 108010051457 Acid Phosphatase Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000972773 Aulopiformes Species 0.000 description 2
• 206010065553 Bone marrow failure Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 241000701822 Bovine papillomavirus Species 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 101150074155 DHFR gene Proteins 0.000 description 2
• 102000012410 DNA Ligases Human genes 0.000 description 2
• 108010061982 DNA Ligases Proteins 0.000 description 2
• 230000009946 DNA mutation Effects 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 241000255925 Diptera Species 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
• 101001131829 Homo sapiens P protein Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 108010000521 Human Growth Hormone Proteins 0.000 description 2
• 102000002265 Human Growth Hormone Human genes 0.000 description 2
• 239000000854 Human Growth Hormone Substances 0.000 description 2
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 108010038452 Interleukin-3 Receptors Proteins 0.000 description 2
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
• 102000004890 Interleukin-8 Human genes 0.000 description 2
• 244000285963 Kluyveromyces fragilis Species 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 101000799460 Mus musculus Thrombopoietin Proteins 0.000 description 2
• OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
• MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 208000001388 Opportunistic Infections Diseases 0.000 description 2
• 239000002033 PVDF binder Substances 0.000 description 2
• 102100036893 Parathyroid hormone Human genes 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 208000020584 Polyploidy Diseases 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 108010059712 Pronase Proteins 0.000 description 2
• LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
• 108020005091 Replication Origin Proteins 0.000 description 2
• 229920005654 Sephadex Polymers 0.000 description 2
• 239000012507 Sephadex™ Substances 0.000 description 2
• 239000012505 Superdex™ Substances 0.000 description 2
• 101150077103 TPO gene Proteins 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 102100034195 Thrombopoietin Human genes 0.000 description 2
• 102000011923 Thyrotropin Human genes 0.000 description 2
• 108010061174 Thyrotropin Proteins 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
• 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
• YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000011149 active material Substances 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 239000000504 antifibrinolytic agent Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 230000006287 biotinylation Effects 0.000 description 2
• 238000007413 biotinylation Methods 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 244000309466 calf Species 0.000 description 2
• 150000001718 carbodiimides Chemical class 0.000 description 2
• 238000012219 cassette mutagenesis Methods 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000011712 cell development Effects 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 210000002421 cell wall Anatomy 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 235000013330 chicken meat Nutrition 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 230000001143 conditioned effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000022811 deglycosylation Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
• 230000030609 dephosphorylation Effects 0.000 description 2
• 238000006209 dephosphorylation reaction Methods 0.000 description 2
• 229960002086 dextran Drugs 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 238000012869 ethanol precipitation Methods 0.000 description 2
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 238000001641 gel filtration chromatography Methods 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
• 239000012561 harvest cell culture fluid Substances 0.000 description 2
• 208000018706 hematopoietic system disease Diseases 0.000 description 2
• 230000011132 hemopoiesis Effects 0.000 description 2
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 102000047119 human OCA2 Human genes 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 230000036737 immune function Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 239000006194 liquid suspension Substances 0.000 description 2
• 230000003343 megakaryocytopoietic effect Effects 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
• 230000000877 morphologic effect Effects 0.000 description 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
• 229960000951 mycophenolic acid Drugs 0.000 description 2
• 229950006780 n-acetylglucosamine Drugs 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
• OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
• 150000003013 phosphoric acid derivatives Chemical group 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 229960005205 prednisolone Drugs 0.000 description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 102000037983 regulatory factors Human genes 0.000 description 2
• 108091008025 regulatory factors Proteins 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 210000003705 ribosome Anatomy 0.000 description 2
• 235000019515 salmon Nutrition 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 229940014800 succinic anhydride Drugs 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 239000001226 triphosphate Substances 0.000 description 2
• 235000011178 triphosphate Nutrition 0.000 description 2
• 101150108727 trpl gene Proteins 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
• 229960002555 zidovudine Drugs 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
• LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
• 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
• BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 1
• VJINKBZUJYGZGP-UHFFFAOYSA-N 3-(1-aminopropylideneamino)propyl-trimethylazanium Chemical compound CCC(N)=NCCC[N+](C)(C)C VJINKBZUJYGZGP-UHFFFAOYSA-N 0.000 description 1
• BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
• ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
• QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• 241000256118 Aedes aegypti Species 0.000 description 1
• 241000256173 Aedes albopictus Species 0.000 description 1
• VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
• 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
• 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
• 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 206010002961 Aplasia Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
• LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
• KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
• FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000351920 Aspergillus nidulans Species 0.000 description 1
• 241000228245 Aspergillus niger Species 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 241001367049 Autographa Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 241000304886 Bacilli Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108700003860 Bacterial Genes Proteins 0.000 description 1
• 241000255789 Bombyx mori Species 0.000 description 1
• 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
• 238000009010 Bradford assay Methods 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 108091067901 CHAPS family Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• 241000272194 Ciconiiformes Species 0.000 description 1
• 235000001258 Cinchona calisaya Nutrition 0.000 description 1
• 108020004638 Circular DNA Proteins 0.000 description 1
• 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010062344 Congenital musculoskeletal anomaly Diseases 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
• 230000007023 DNA restriction-modification system Effects 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 241000255601 Drosophila melanogaster Species 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 108010066486 EGF Family of Proteins Proteins 0.000 description 1
• 102000018386 EGF Family of Proteins Human genes 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 241000702224 Enterobacteria phage M13 Species 0.000 description 1
• 101710146739 Enterotoxin Proteins 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 1
• 201000006328 Fanconi syndrome Diseases 0.000 description 1
• 102000008857 Ferritin Human genes 0.000 description 1
• 108050000784 Ferritin Proteins 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• MURGITYSBWUQTI-UHFFFAOYSA-N Fluorescin Natural products OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 1
• 206010016880 Folate deficiency Diseases 0.000 description 1
• 241000700662 Fowlpox virus Species 0.000 description 1
• 108010058643 Fungal Proteins Proteins 0.000 description 1
• 241000237858 Gastropoda Species 0.000 description 1
• 108700023863 Gene Components Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
• 102100022624 Glucoamylase Human genes 0.000 description 1
• 102000030595 Glucokinase Human genes 0.000 description 1
• 108010021582 Glucokinase Proteins 0.000 description 1
• 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
• 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
• YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 241000219146 Gossypium Species 0.000 description 1
• 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 101100508941 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) ppa gene Proteins 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 102000005548 Hexokinase Human genes 0.000 description 1
• 108700040460 Hexokinases Proteins 0.000 description 1
• 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 description 1
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
• 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
• 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 206010053317 Hydrophobia Diseases 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 108010004250 Inhibins Proteins 0.000 description 1
• 102000002746 Inhibins Human genes 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
• 102000010786 Interleukin-5 Receptors Human genes 0.000 description 1
• 108010038484 Interleukin-5 Receptors Proteins 0.000 description 1
• 102100026019 Interleukin-6 Human genes 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 101710177504 Kit ligand Proteins 0.000 description 1
• 241000235649 Kluyveromyces Species 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical group NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 240000004322 Lens culinaris Species 0.000 description 1
• 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 102000013967 Monokines Human genes 0.000 description 1
• 108010050619 Monokines Proteins 0.000 description 1
• 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
• VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 241000221961 Neurospora crassa Species 0.000 description 1
• 101100190845 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pmp-1 gene Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 230000004989 O-glycosylation Effects 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108010087702 Penicillinase Proteins 0.000 description 1
• 241000228143 Penicillium Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000015731 Peptide Hormones Human genes 0.000 description 1
• 108010038988 Peptide Hormones Proteins 0.000 description 1
• 240000007377 Petunia x hybrida Species 0.000 description 1
• 102000001105 Phosphofructokinases Human genes 0.000 description 1
• 108010069341 Phosphofructokinases Proteins 0.000 description 1
• 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108010003044 Placental Lactogen Proteins 0.000 description 1
• 239000000381 Placental Lactogen Substances 0.000 description 1
• 108700001094 Plant Genes Proteins 0.000 description 1
• 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
• 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• SVXXJYJCRNKDDE-AVGNSLFASA-N Pro-Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CN=CN1 SVXXJYJCRNKDDE-AVGNSLFASA-N 0.000 description 1
• 108010076181 Proinsulin Proteins 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 102100024819 Prolactin Human genes 0.000 description 1
• 108010002519 Prolactin Receptors Proteins 0.000 description 1
• 102100029000 Prolactin receptor Human genes 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 101710127913 Proteoglycan 4 Proteins 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
• 102000013009 Pyruvate Kinase Human genes 0.000 description 1
• 108020005115 Pyruvate Kinase Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 102000004879 Racemases and epimerases Human genes 0.000 description 1
• 108090001066 Racemases and epimerases Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108090000103 Relaxin Proteins 0.000 description 1
• 102000003743 Relaxin Human genes 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 239000012506 Sephacryl® Substances 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 240000003768 Solanum lycopersicum Species 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 102000013275 Somatomedins Human genes 0.000 description 1
• 102100021941 Sorcin Human genes 0.000 description 1
• 101710089292 Sorcin Proteins 0.000 description 1
• 241000256248 Spodoptera Species 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 241000269319 Squalius cephalus Species 0.000 description 1
• 108700034501 Staphylococcus aureus auR Proteins 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 101000799463 Sus scrofa Thrombopoietin Proteins 0.000 description 1
• 241000255588 Tephritidae Species 0.000 description 1
• 241000589500 Thermus aquaticus Species 0.000 description 1
• COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 101710113649 Thyroid peroxidase Proteins 0.000 description 1
• 241001149964 Tolypocladium Species 0.000 description 1
• 102000003929 Transaminases Human genes 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
• FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
• 241000223259 Trichoderma Species 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
• 244000000188 Vaccinium ovalifolium Species 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 241000235013 Yarrowia Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000037919 acquired disease Diseases 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 238000005054 agglomeration Methods 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 230000016571 aggressive behavior Effects 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 108010035879 albumin-bilirubin complex Proteins 0.000 description 1
• 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• JIWBIWFOSCKQMA-LTKCOYKYSA-N all-cis-octadeca-6,9,12,15-tetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O JIWBIWFOSCKQMA-LTKCOYKYSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
• 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000000868 anti-mullerian hormone Substances 0.000 description 1
• 230000001494 anti-thymocyte effect Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000012223 aqueous fraction Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000001491 aromatic compounds Chemical class 0.000 description 1
• 208000005266 avian sarcoma Diseases 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000010836 blood and blood product Substances 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 229940125691 blood product Drugs 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 210000004970 cd4 cell Anatomy 0.000 description 1
• XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
• 229960000603 cefalotin Drugs 0.000 description 1
• 238000010370 cell cloning Methods 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 108091092328 cellular RNA Proteins 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 230000007073 chemical hydrolysis Effects 0.000 description 1
• 108700010039 chimeric receptor Proteins 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000014107 chromosome localization Effects 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000005757 colony formation Effects 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 208000016598 congestive splenomegaly Diseases 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000037029 cross reaction Effects 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• 230000009849 deactivation Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 239000012954 diazonium Substances 0.000 description 1
• IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
• FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 229910001882 dioxygen Inorganic materials 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 239000000147 enterotoxin Substances 0.000 description 1
• 230000007071 enzymatic hydrolysis Effects 0.000 description 1
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 239000006167 equilibration buffer Substances 0.000 description 1
• 210000000267 erythroid cell Anatomy 0.000 description 1
• 210000003013 erythroid precursor cell Anatomy 0.000 description 1
• 230000000913 erythropoietic effect Effects 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 230000008713 feedback mechanism Effects 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 102000018146 globin Human genes 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 229940076085 gold Drugs 0.000 description 1
• 210000004368 gonadotroph Anatomy 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 150000002357 guanidines Chemical class 0.000 description 1
• 238000001631 haemodialysis Methods 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 230000000322 hemodialysis Effects 0.000 description 1
• 230000002439 hemostatic effect Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 235000014304 histidine Nutrition 0.000 description 1
• 102000055229 human IL4 Human genes 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 208000019188 inherited aplastic anemia Diseases 0.000 description 1
• 239000000893 inhibin Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 239000001573 invertase Substances 0.000 description 1
• 235000011073 invertase Nutrition 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 238000013493 large scale plasmid preparation Methods 0.000 description 1
• 108010030727 lens intermediate filament proteins Proteins 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 230000001589 lymphoproliferative effect Effects 0.000 description 1
• 230000012976 mRNA stabilization Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 210000002894 multi-fate stem cell Anatomy 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• IBXUUHQMQWBEMC-UHFFFAOYSA-N n-methyl-4-sulfanylbutanamide Chemical compound CNC(=O)CCCS IBXUUHQMQWBEMC-UHFFFAOYSA-N 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 238000011330 nucleic acid test Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000011369 optimal treatment Methods 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 230000002138 osteoinductive effect Effects 0.000 description 1
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229950009506 penicillinase Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000003836 peripheral circulation Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 238000002205 phenol-chloroform extraction Methods 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 229940117953 phenylisothiocyanate Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 108010054442 polyalanine Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 208000007232 portal hypertension Diseases 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 230000001581 pretranslational effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 108010087851 prorelaxin Proteins 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000000734 protein sequencing Methods 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
• FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 1
• 229960001327 pyridoxal phosphate Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 229960001404 quinidine Drugs 0.000 description 1
• 229960000948 quinine Drugs 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000009711 regulatory function Effects 0.000 description 1
• 230000020874 response to hypoxia Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• 229940048086 sodium pyrophosphate Drugs 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
• 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000009210 therapy by ultrasound Methods 0.000 description 1
• 229920002397 thermoplastic olefin Polymers 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
• 230000003022 thrombocytopoietic effect Effects 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
• 230000001256 tonic effect Effects 0.000 description 1
• 210000003014 totipotent stem cell Anatomy 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1